Finance

Lists
Outlook: 11.8% bullish·35.3% bearish
Go to analysis
BMYB34:BVMF
Bristol-Myers Squibb Company BDR
331,90 R$
+0,65%
(+2,15) 1D
30 սեպ, 11:31:25 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BMYB34...
Mkt. cap
120,77 մլրդ
Avg. vol.
3,00
Volume
0,00
52-wk high
347,15 R$
52-wk low
221,72 R$
Shares outstanding
2,04 մլրդ
No. of employees
32 հզր
Mkt. cap
120,77 մլրդ
Avg. vol.
3,00
Volume
0,00
52-wk high
347,15 R$
52-wk low
221,72 R$
Shares outstanding
2,04 մլրդ
No. of employees
32 հզր
News stories
From web sources and news partners
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees32,5 հզր
Founded1887
HeadquartersՆյու Յորք, Նյու Յորք, Միացյալ Նահանգներ
Sector-
Websitebms.com
Last report
30 հլս, 2026 թ.
Fiscal period
Q2 2026
2,04 $ / 1,60 $
+27,74%beat
Revenue / Est. (USD)
12,97 մլրդ / 11,74 մլրդ
+10,53%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
12,22 մլրդ
12,50 մլրդ
11,49 մլրդ
12,97 մլրդ
Cost of goods sold
3,31 մլրդ
3,51 մլրդ
3,41 մլրդ
3,71 մլրդ
Cost of revenue
3,31 մլրդ
3,51 մլրդ
3,41 մլրդ
3,71 մլրդ
Research and development expenses
2,43 մլրդ
2,56 մլրդ
2,24 մլրդ
2,54 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,79 մլրդ
2,09 մլրդ
1,61 մլրդ
1,82 մլրդ
Operating expense
5,05 մլրդ
5,47 մլրդ
4,28 մլրդ
4,80 մլրդ
Total operating expenses
8,36 մլրդ
8,98 մլրդ
7,69 մլրդ
8,51 մլրդ
Operating income
3,86 մլրդ
3,52 մլրդ
3,80 մլրդ
4,46 մլրդ
Other non operating income
529,00 մլն
544,00 մլն
125,00 մլն
106,00 մլն
EBT including unusual items
3,11 մլրդ
1,47 մլրդ
3,24 մլրդ
4,09 մլրդ
EBT excluding unusual items
4,07 մլրդ
3,86 մլրդ
3,65 մլրդ
4,35 մլրդ
Income tax expense
919,00 մլն
384,00 մլն
561,00 մլն
770,00 մլն
Effective tax rate
29,51%
26,12%
17,32%
18,84%
Other operating expenses
-
-
-
-
Net income
2,20 մլրդ
1,09 մլրդ
2,68 մլրդ
3,32 մլրդ
Net profit margin
18,01%
8,69%
23,30%
25,57%
Earnings per share
1,63
1,26
1,58
2,04
Interest and investment income
161,00 մլն
148,00 մլն
104,00 մլն
101,00 մլն
Interest expense
-482,00 մլն
-432,00 մլն
-406,00 մլն
-403,00 մլն
Net interest expenses
-321,00 մլն
-284,00 մլն
-302,00 մլն
-302,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
4,91 մլրդ
4,54 մլրդ
4,41 մլրդ
5,08 մլրդ
Gain or loss from assets sale
-9,00 մլն
-
-34,00 մլն
-142,00 մլն
AI content may include mistakes. Learn more
Google Apps